EP3515456A4 - COMPOSITIONS AND METHODS FOR CHARACTERIZING THE REACTIVITY OF SOLID TUMORS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY - Google Patents
COMPOSITIONS AND METHODS FOR CHARACTERIZING THE REACTIVITY OF SOLID TUMORS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY Download PDFInfo
- Publication number
- EP3515456A4 EP3515456A4 EP17853747.8A EP17853747A EP3515456A4 EP 3515456 A4 EP3515456 A4 EP 3515456A4 EP 17853747 A EP17853747 A EP 17853747A EP 3515456 A4 EP3515456 A4 EP 3515456A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- responsiveness
- compositions
- methods
- solid tumors
- antibody monotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662397062P | 2016-09-20 | 2016-09-20 | |
PCT/US2017/052246 WO2018057506A1 (en) | 2016-09-20 | 2017-09-19 | Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3515456A1 EP3515456A1 (en) | 2019-07-31 |
EP3515456A4 true EP3515456A4 (en) | 2020-06-17 |
Family
ID=61691137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17853747.8A Withdrawn EP3515456A4 (en) | 2016-09-20 | 2017-09-19 | COMPOSITIONS AND METHODS FOR CHARACTERIZING THE REACTIVITY OF SOLID TUMORS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3515456A4 (zh) |
JP (1) | JP2019529437A (zh) |
CN (1) | CN109963572A (zh) |
WO (1) | WO2018057506A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
SI3631454T1 (sl) | 2017-05-30 | 2023-12-29 | Bristol-Myers Squibb Company | Zdravljenje lag-3 pozitivnih tumorjev |
WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
EP4010022A4 (en) * | 2019-08-09 | 2024-01-17 | The Regents Of Univ Of California | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF BLADDER CANCER |
WO2023064784A1 (en) * | 2021-10-12 | 2023-04-20 | Foundation Medicine, Inc. | Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150071910A1 (en) * | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2016034718A1 (en) * | 2014-09-05 | 2016-03-10 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2701378C2 (ru) * | 2013-03-15 | 2019-09-26 | Дженентек, Инк. | Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний |
-
2017
- 2017-09-19 WO PCT/US2017/052246 patent/WO2018057506A1/en unknown
- 2017-09-19 JP JP2019515363A patent/JP2019529437A/ja active Pending
- 2017-09-19 CN CN201780070587.5A patent/CN109963572A/zh active Pending
- 2017-09-19 EP EP17853747.8A patent/EP3515456A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150071910A1 (en) * | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2016034718A1 (en) * | 2014-09-05 | 2016-03-10 | Medimmune Limited | Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma) |
Non-Patent Citations (2)
Title |
---|
B.W.HIGGS ET AL: "High tumoral IFNg mRNA, PD-L1 protein, and combined IFNg mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients", 15LBA, 1 September 2015 (2015-09-01), pages S717, XP055691692, Retrieved from the Internet <URL:https://www.ejcancer.com/article/S0959-8049(16)31937-2/abstract> [retrieved on 20200505] * |
See also references of WO2018057506A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018057506A1 (en) | 2018-03-29 |
EP3515456A1 (en) | 2019-07-31 |
CN109963572A (zh) | 2019-07-02 |
JP2019529437A (ja) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201900353B (en) | Anti-pd-l1 antibodies | |
IL262295A (en) | Antibodies against pd-l1 | |
HK1252955A1 (zh) | 針對程序性死亡配體(pd-l1)的單域抗體及其衍生蛋白 | |
EP3325513A4 (en) | Anti-pd-l1 antibodies and uses thereof | |
EP3459597A4 (en) | ANTI-CTLA4 SINGLE DOMAIN ANTIBODIES AND PROTEIN DERIVED THEREFROM | |
EP3400243A4 (en) | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | |
EP3433277A4 (en) | NEW ANTIBODIES AGAINST PD-L1 | |
IL258214A (en) | Antibodies - anti-pd-1 and preparations | |
EP3532100A4 (en) | ANTI-PD-L1 ANTIBODIES AND VARIANTS | |
EP3332006A4 (en) | NEW ANTI-PD-L1 ANTIBODIES | |
EP3242894A4 (en) | Anti-pd-l1 antibodies | |
EP3307777A4 (en) | NOVEL ANTI-PD-L1 ANTIBODIES | |
EP3515456A4 (en) | COMPOSITIONS AND METHODS FOR CHARACTERIZING THE REACTIVITY OF SOLID TUMORS TO ANTI-PD-L1 ANTIBODY MONOTHERAPY | |
EP3177649A4 (en) | Anti-pd-l1 antibodies | |
EP3448428A4 (en) | COMPOSITIONS COMPRISING ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODY CO-FORMULATION | |
EP3060581A4 (en) | Anti-pd-l1 monoclonal antibodies and fragments thereof | |
EP3316909A4 (en) | ANTI-NTB-A ANTIBODIES AND ASSOCIATED COMPOSITIONS AND METHODS | |
EP3565596A4 (en) | PROCESSES AND COMPOSITIONS RELATING TO ANTI-CHI3LI ANTIBODY REAGENTS | |
EP3441086A4 (en) | MONOCLONAL ANTI-PD-1 ANTIBODY | |
EP3310719A4 (en) | Compositions and methods for analytical sample preparation | |
EP3373950A4 (en) | METHOD AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICATIONS | |
EP3464610A4 (en) | PROTEIN COMPOSITION AND METHODS FOR MICROBIOTE ANALYSIS | |
HK1256804A1 (zh) | 抗cd154抗體及其使用方法 | |
EP3294341A4 (en) | COMPOSITIONS AND METHOD FOR THE PRODUCTION OF ANTIBODY CONJUGATES | |
EP3672636A4 (en) | PROCEDURES AND COMPOSITIONS RELATED TO ANTI-CHI3L1 ANTIBODY REAGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190423 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200514 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101ALI20200508BHEP Ipc: A61P 35/00 20060101ALI20200508BHEP Ipc: C12N 15/113 20100101ALI20200508BHEP Ipc: A61K 31/7088 20060101AFI20200508BHEP Ipc: A61K 39/00 20060101ALI20200508BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40011692 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20201215 |